Acquired by Angiotech, Oct. 2005

Afmedica

Afmedica, a privately held drug coated device company located in Kalamazoo, Michigan, was founded in 2002 by the Apjohn Group and the Fischell family. This pre-clinical stage company is focused on commercializing its broad intellectual property covering anti-proliferative, cyto-static drugs such as Sirolimus, on a variety of devices for the prevention of scar tissue formation after surgical procedures.

Co-Investors: TGap Ventures, Angels

Founded in early 2000 with operations in Detroit, Michigan and Royston, England, Asterand operates one of the world's largest human tissue banks with many types of cancer, cardiovascular disease, rheumatoid arthritis and CNS disease. Asterand provides tissues and services for pharmaceutical research & clinical development.

Co-Investors: Oxford Bioscience Partners, Fort Washington Capital Partners, Chrysalis Ventures, Arboretum Ventures

Founded in 1998 by Edwin Cohen, founder and former Chairman and CEO of Barr Laboratories, Intranasal Therapeutics, Inc. (ITI) is a specialty pharmaceutical company focused on developing innovative nasally delivered pharmaceutical products, with a particular focus on drugs treating pain and disorders related to the central nervous system. Several products are in the Phase II human studies.

Co-Investors: SV Life Sciences, Tullis-Dickerson, Burrill & Company, Fidelty Biosciences, Fort Washington Capital Partners, Fletcher-Spaght

Based in St Louis Missouri, Kereos develops targeted therapeutics and molecular imaging agents that detect and attack cancer and cardiovascular disease. The company's diagnostic imaging product enters the clinic in 2008.

Co-Investors: Prolog Ventures, Charter Life Sciences, RiverVest Ventures, Triathlon Medical Ventures, Phillips Medical, Sigvion Ventures, and Lux Ventures

An Afmedica spin-out company, MedElute is a preclinical stage drug-eluting materials company focused on treating post-surgical adhesions using a highly novel anti-platelet approach. MedElute was founded in 2005 and is based in Kalamazoo, Michigan.

Co-Investors: Ann Arbor SPARK, Angels

Nephrion, Inc.

www.nephrion.com

Nephrion is a clinical stage medical device company founded in 2007 on intellectual property from the University of Michigan and RenaMed Biologics. Based in Ann Arbor, Nephrion is focused on patients suffering from severe inflammatory disease associated with renal and cardio failures.

Co-Investors: Lurie Investments, NorthCoast Technology Ventures, Diamond Capital (Dow)

ProNAi Therapeutics, Inc. of Kalamazoo, Michigan, is an emerging biopharmaceutical company that is leveraging its novel and proprietary nucleic acid-based interfering technology, DNAi, to advance a next generation of therapies for patients with cancer and other complex genetic diseases. ProNAi filed its first DNAi-based IND in cancer in 2008 and is seeking partners.

Co-Investors: BRCC, Grand Angels, MI Angels, State of Michigan, Sigvion Ventures

RenaMed Biologics, a University of Michigan spin-out from the late 90s, is a clinical stage cellular therapy company dedicated to the design, development, and commercialization of human cell replacement systems. RenaMed’s products provide targeted and comprehensive kidney cell therapy for patients suffering from severe inflammatory disease states such as Acute Renal Failure.

Co-Investors: Lurie Investments, Seaflower Ventures, Bio*One Capital, BD Ventures, NorthCoast Technology Ventures, TVM Capital, MDS Capital, Diamond Capital (Dow), Merlin BioMed, Portage Ventures, CDP capital, Foster & Foster, Palmero Group, Genzyme

Svelte Medical Systems, based in New Jersey, is a clinical stage medical device company with a novel “stent on a wire’ delivery system for safe and easier cardiac stent procedures.

Co-Investors: Fischell Family, SMS Ventures, Angels

ZyStor, based in Milwaukee Wisconsin, is a biotechnology company developing innovative therapeutics that will significantly improve the lives of patients who suffer from genetic disorders known as lysosomal storage diseases (LSDs). The company's lead Pompe drug is poised to enter the clinic in 2009.

Co-Investors: Mason-Wells, Prolog Ventures, Venture Investors, State of Wisconsin Investment Board, Hexagon Investments, Stonehenge Capital